Pharsight

Venlafaxine Besylate patents expiration

VENLAFAXINE BESYLATE IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6717015 ALMATICA Venlafaxine besylate
Mar, 2023

(1 year, 1 month ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7776358 ALMATICA Extended release venlafaxine besylate tablets
May, 2028

(3 years from now)

Venlafaxine Besylate is owned by Almatica.

Venlafaxine Besylate contains Venlafaxine Besylate.

Venlafaxine Besylate has a total of 2 drug patents out of which 1 drug patent has expired.

Expired drug patents of Venlafaxine Besylate are:

  • US6717015

Venlafaxine Besylate was authorised for market use on 29 June, 2022.

Venlafaxine Besylate is available in tablet, extended release;oral dosage forms.

Venlafaxine Besylate can be used as treatment of depression and generalized anxiety disorder.

The generics of Venlafaxine Besylate are possible to be released after 16 May, 2028.

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using VENLAFAXINE BESYLATE ingredient

Market Authorisation Date: 29 June, 2022

Treatment: Treatment of depression and generalized anxiety disorder

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage

VENLAFAXINE BESYLATE family patents

Family Patents